
Lantheus Holdings (LNTH) Stock Forecast & Price Target
Lantheus Holdings (LNTH) Analyst Ratings
Bulls say
Lantheus Holdings Inc is experiencing a positive upward trajectory in the precision diagnostics market, particularly with its product POSLUMA, which is projected to achieve high-single-digit revenue and unit share in PSMA PET imaging by the first quarter of 2025, a notable increase from its current market position. The recent enhancements to the Pylarify formulary, which will increase batch sizes by approximately 50%, along with three years of TPT eligibility, are anticipated to significantly boost growth for Pylarify starting in the fourth quarter of 2026. Additionally, there are expectations of improved unit and price growth in the third quarter of 2026, setting the stage for further market share recovery and development in the latter part of the year.
Bears say
Lantheus Holdings Inc has experienced a decline in its growth trajectory, with its two-year growth profile now lagging behind that of its profitable SMID MedTech peers due to lowered PYL growth forecasts for 2025-2026. The company's Pylarify product reported revenues of $260 million, reflecting an 8% year-over-year decrease and a significant shortfall of approximately $14 million compared to consensus estimates. Additionally, there has been a disappointing unit growth rate of only 2% year-over-year, coupled with a 10% price headwind in the latest quarter, further exacerbating the negative financial outlook.
This aggregate rating is based on analysts' research of Lantheus Holdings and is not a guaranteed prediction by Public.com or investment advice.
Lantheus Holdings (LNTH) Analyst Forecast & Price Prediction
Start investing in Lantheus Holdings (LNTH)
Order type
Buy in
Order amount
Est. shares
0 shares